Prevalence of COVID-19-associated Kidney Injury in ICU and Prognosis of Proximal Tubular Injury in ARDS: the URICOV Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- COVID-19 Acute Respiratory Distress Syndrome
- Sponsor
- Assistance Publique Hopitaux De Marseille
- Enrollment
- 130
- Locations
- 1
- Primary Endpoint
- Evaluation of the incidence of acute kidney injury and tubular dysfunction
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
In addition to respiratory involvement, SARS-CoV 2, the virus responsible for coronavirus 2019 or Covid-19, appears to be responsible for renal involvement such as acute renal failure or proteinuria, so the mechanisms are not known at this time. The consequences of Covid-19 on renal function in the short and long term are not known.
It is important to be able to better document these renal impairments to understand the mechanisms of this disease.
The main objective of this study is to describe the prevalence of Covid-19-related renal damage (acute renal failure, proteinuria, microalbuminuria, hematuria) in a large cohort of patients in intensive care for SARS-CoV 2 infection with severe respiratory impairment.
The other objectives will be to evaluate in this cohort the impact of these renal impairments on the severity of the Covid-19 disease, and to compare them to the renal impairments of patients in intensive care for acute respiratory distress syndrome (ARDS) due to other respiratory diseases.
Blood and urine samples will be taken at the time of intubation in all critically ill patients with respiratory distress requiring mechanical ventilation for Covid-19 or other cause of respiratory distress with PaO2/FiO2 ratio < 300.
Patients will be followed for the duration of their ICU and hospital stay. Data will be collected prospectively in three ICUs in the University Hospitals of Marseille.
Investigators
Eligibility Criteria
Inclusion Criteria
- •• Displaying acute respiratory distress Needing invasive mechanical ventilation
- •With PaO2/FiO2 ratio \< 300 after orotracheal intubation
Exclusion Criteria
- •Patients in ICU following thoracic surgery or lung transplantation
- •Patients with cardiogenic pulmonary oedema
- •Patients with end stage kidney disease
- •Moribund patients
Outcomes
Primary Outcomes
Evaluation of the incidence of acute kidney injury and tubular dysfunction
Time Frame: First 24 hours after orotracheal intubation
We aimed to perform a detailed analysis of urinary markers of kidney dysfunction with urine protein electrophoresis and tubular protein dosage in a prospective cohort of critically ill patients in ICU for ARDS due to COVID-19 in the first 24 hours following orotracheal intubation, to evaluate the incidence of acute kidney injury (AKI) and tubular dysfunction among critically ill patients with COVID-19-related ARDS at the onset of Mechanical ventilation, and to specify which part of the kidney parenchyma is involved.